This randomized clinical trial analyzes whether exercise, glucagon-like peptide-1 (GLP-1) receptor agonist treatment, or their combination preserve site-specific bone mineral density for individuals with obesity undergoing weight loss intervention. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.